POSC · XBRL financial data
Positron financial statements, every fiscal year
The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (POSC's year ends in late December)
| In millions of dollars | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | †Dec 31, 2014 | †Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | 7 | 3 | 2 | 1 | 0 |
| Revenue from contracts with customers | — | — | — | — | 0 |
| Cost of goods and services sold | 6 | 2 | 1 | 1 | 3 |
| Gross profit | 0 | 1 | 0 | 0 | (2) |
| Research and development | 1 | 1 | 1 | 0 | — |
| General and administrative | 2 | 4 | 3 | 2 | 8 |
| Total operating expenses | 5 | 6 | 4 | 3 | — |
| Operating income (loss) | (4) | (5) | (3) | (3) | (10) |
| Interest expense | 1 | 2 | 2 | 2 | 0 |
| Other income (expense) | 0 | (0) | (0) | 1 | — |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | — |
| Net income (loss) | (6) | (8) | (7) | (3) | (11) |
| Earnings per share, basic USD per share | — | — | — | — | (0.34) |
| Earnings per share, diluted USD per share | — | — | — | — | (0.34) |
| Weighted average shares, basic millions of shares | — | — | — | — | 31 |
| Weighted average shares, diluted millions of shares | — | — | — | — | 31 |
- † Share count changed about 4x in the period ending 2014-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/174 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (POSC's year ends in late December)
| In millions of dollars | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | †Dec 31, 2014 | †Dec 31, 2025 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 0 | 0 | 2 | 0 | 3 |
| Accounts receivable | 1 | 0 | 0 | 0 | 0 |
| Inventory | 1 | 1 | 1 | 0 | 1 |
| Total current assets | 2 | 1 | 3 | 1 | 3 |
| Property and equipment, net | 0 | 1 | 1 | 1 | 0 |
| Right-of-use asset | — | — | — | — | 0 |
| Goodwill | — | 0 | 0 | 0 | — |
| Total assets | 2 | 3 | 4 | 2 | 4 |
| Total current liabilities | 5 | 8 | 15 | 3 | 2 |
| Total deposits | — | 0 | 0 | 0 | 0 |
| Lease liability, non-current | — | — | — | — | 0 |
| Total liabilities | 5 | 9 | 15 | 3 | 3 |
| Accumulated deficit | (108) | (116) | (123) | (126) | (145) |
| Total stockholders' equity | (3) | (6) | (11) | (1) | 1 |
| Total liabilities and equity | 2 | 3 | 4 | 2 | 4 |
| Common shares outstanding (cover page) millions of shares | 1,103 | 1,452 | 1,453 | 5,710 | 33 |
- † Share count changed about 4x in the period ending 2014-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/174 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (POSC's year ends in late December)
| In millions of dollars | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | †Dec 31, 2014 | †Dec 31, 2025 |
|---|---|---|---|---|---|
| Net income (loss) | (6) | (8) | (7) | (3) | (11) |
| Stock-based compensation | 0 | 2 | 1 | 0 | 5 |
| Net cash from operating activities | (4) | (2) | (3) | — | (5) |
| Purchases of property and equipment | 0 | 0 | 0 | 0 | — |
| Net cash from investing activities | (0) | (0) | (0) | — | (0) |
| Proceeds from issuing common stock | 0 | 0 | 0 | 1 | 10 |
| Net cash from financing activities | 3 | 3 | 5 | — | 7 |
| Net change in cash | — | — | — | — | 2 |
- † Share count changed about 4x in the period ending 2014-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 1/174 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Positron | 0.4 | 0.1 | (1)* | 32.8M | 0.3 quarters | 10-QJun 30, 2026 |
| Vivos Therapeutics | 1.8 | 5.2 | (3.1)* | 20.1M | 0.6 quarters | 10-QJun 30, 2026 |
| Allurion Technologies | 5.1 | 2.9 | (3.2) | 15.0M | 1.6 quarters | 10-QMar 31, 2026 |
| Neuraxis | 8.3 | 1.9 | (1)* | 12.6M | — | 10-QJun 30, 2026 |
| Dror Ortho-Design | 0.1 | not reported | (0.3)* | 977.0M | 0.3 quarters | 10-QJun 30, 2026 |
| United Health Products | 0 | 0 | (0.1)* | 262.7M | 0.2 quarters | 10-QJun 30, 2026 |
| Neuroone Medical Technologies | 2 | 2 | (1.1)* | 9.1M | 1.9 quarters | 10-QJun 30, 2026 |
| Precision Optics | 9.8 | 8.8* | (0.6)* | 11.0M | 15.2 quarters | 10-KJun 30, 2026 |
| RenovoRx | 9.5 | 0.9 | (2.9)* | 45.1M | 3.3 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.